Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexanabinol in advanced tumours
NCT02423239Phase 1Unknown
- Sponsor
- e-therapeutics plc
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of Dexanabinol in hepatocellular carcinoma (HCC), pancreatic cancer (PC) and solid tumor (3 arms), sponsored by e-therapeutics plc. Primary endpoints: Maximum Tolerated Dose at 29 days and Adverse Events. Status: unknown.
02
Drugs
Dexanabinol
03
Conditions
hepatocellular carcinoma (HCC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT02423239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423239.